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Abstract
Drug combinations have been increasingly applied in chemotherapy as a strategy to enhance the efﬁcacy of anti-
cancer treatment. The appropriate drug combinations may achieve synergistic effects beyond monotherapies alone.
AC220 (Quizartinib), an FLT3 receptor tyrosine kinase inhibitor, developed for the treatment of AML, has been tested in
phase II human clinical trials. However, AC220 as a monotherapy is not efﬁcacious enough. In this study, we performed
a small-molecule screening of 12 640 compounds in order to ﬁnd a compound that increase the AC220 efﬁcacy in
chemotherapy. We identiﬁed that TAK-165, a HER2 inhibitor, even when used at low nanomolar doses in combination
with AC220, was able to induce cell death in different cancer cells, but not in non-cancer cell lines. We showed that
TAK-165 and AC220 act synergistically to downregulate key signaling pathways and potently induce cancer cell death.
Furthermore, we demonstrated that TAK-165 inhibited autophagy in a HER2-independent manner. Finally, we showed
that the combination of TAK-165 and AC220 induced cell death in cancer cells through the activation of chaperone-
mediated autophagy. Overall, these ﬁndings support the strategy for using AC220 and an autophagy inhibitor such as
TAK-165 in a combinatorial treatment to enhance the efﬁcacy of cancer therapies.
Introduction
FLT3, a member of receptor tyrosine kinase III family, is
highly expressed in normal bone marrow cells, early pro-
genitor cells and hematopoietic stem cells. FLT3 stimulation
promotes cell proliferation by activating phosphoinositol-3-
kinase (PI3K), Ras GTPase, protein kinase B (Akt) and
mitogen-activated protein kinase (MAPK) pathways1.
Cancer-related FLT3 mutations in leukemia, especially acute
myeloid leukemia (AML), can induce ligand-independent
activation of the receptor and promote proliferation of
hematological tumor cells2–4. Thus, FLT3 has been recog-
nized as a promising target in AML chemotherapy. AC220
(also called Quizartinib), a potent and selective inhibitor of
FLT3, was developed for AML treatment and had been
tested in phase II human clinical trials5. AC220 was shown
to be a highly speciﬁc for FLT3 in a kinome proﬁling
experiment6. In addition, AC220 has demonstrated accep-
table pharmacokinetic properties and pharmacokinetic
proﬁle, as well as efﬁcacy and tolerability in xenographic
tumor models and in humans6,7. Although the early clinical
studies have shown promising outcomes for AC220 as a
monotherapy, cancer recurrence in AML patients treated
with AC220 has suggested difﬁculty in using AC220 as
monotherapy. AC220 in combination with other che-
motherapeutic agents has been shown to improve disease
recurrence rates in AML7–9. The use of AC220 in other
types of cancers has not been well-explored.
Autophagy is an evolutionarily conserved mechanism
that functions to promote the degradation and recycling
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of cellular components through lysosomes10–12. Autop-
hagy is activated in eukaryotic cells as an adaptive and
survival mechanism in response to stress and starvation in
order to maintain cellular homeostasis. Autophagy acti-
vation has been shown to be an important regulator of
cancer development and progression and thus, inhibition
of autophagy has been considered as a possible anti-
cancer therapy, such as in combination therapies with the
use of chemotherapeutic agents that can inhibit autop-
hagy13–15. Consistently, inhibition of autophagy has been
shown to decrease tumor growth, as activation of autop-
hagy can protect against genotoxic stress13. Here we
screened the ICCB Known Bioactive library of 12,640
compounds for the enhancement of the cytotoxicity of
AC220 and identiﬁed TAK-165, a potent and irreversible
HER2 (encoded by ERBB2) inhibitor, as a compound that
can effectively induce cell death in different cancer cell
lines when used in combined therapy with AC220. We
demonstrated that TAK-165 could act as an autophagy
inhibitor by a HER2-independent mechanism and induce
cell death through chaperone-mediated autophagy when
used in combination with AC220. The identiﬁcation of
TAK-165 as an autophagy inhibitor and its high efﬁcacy in
killing cancer cells when combined with AC220 suggests
the possibility of inhibiting autophagy in a combination
therapy for combating resistance to cancer treatment.
Results
TAK-165 in a combinatorial treatment with AC220 induces
cell death in different cancer cell lines
In order to ﬁnd a compound that could enhance AC220
efﬁcacy in chemotherapy, we performed a small-
molecule screening of 12,640 compounds from the
ICCB Known Bioactive library. This high-throughput
screening was performed on ES-2 cells, which express
FLT3 (ref16.), using a luminescence-based viability assay.
From the primary screening, 45 primary hits were
obtained (Fig. 1a, b), and after validations in secondary
assays, TAK-165 was identiﬁed (Fig. 1c) as a compound
that was able to induce cell death when combined with
AC220. TAK-165 was originally identiﬁed as a selective,
irreversible and potent HER2 inhibitor17. TAK-165
demonstrated no cytotoxicity in ES-2 cells when used
as a single treatment, however, it was able to reduce cell
viability in a dose- and time-dependent manner when
treated in combination with AC220 (Fig. 1d and Sup-
plementary Fig. 1A). We also tested whether TAK-165/
AC220 combination could affect the viability of other
cancer cell lines, including those derived from AML and
breast cancer. We found that both breast cancer cell lines
(BCAP-37, MCF-7 and Sum159) as well as AML cell lines
(HEL, MOLM-14 and OCI-AML3) showed signiﬁcant
reduction of viability when treated with the combination
TAK-165/AC220 (Fig. 2a, b, Supplementary Fig. 1B and
1C). The triple negative breast cancer cell lines (Sum149
and HCC1937), which are negative for estrogen recep-
tors, progesterone receptors, and HER218, also showed a
signiﬁcant loss of viability after treatment with TAK-165
and AC220 (Fig. 2c). On the other hand, the TAK-165/
AC220 combination did not show a signiﬁcant effect on
viability of non-cancer cell lines, as MDCK and MRC-5
SV2 (Fig. 2d). This suggests that the TAK-165/AC220
combination may be promising for the treatment of dif-
ferent types of cancer.
TAK-165 has a synergistic effect with AC220 in inhibiting
proliferation signaling
The combination index may be used to determine if a
drug combination may have additive or synergistic
effects19–21. We determined the combination index
between the TAK-165 and AC220, in order to assess
whether the viability loss in tumor cells by the combina-
tion treatment may have synergistic action between these
two compounds. We found that the combination index of
combined treatment with TAK-165 and AC220 on ES-2
cells (Fig. 3a) and on two AML cell lines, HEL (Fig. 3b)
and OCI-AML3 (Fig. 3c) all showed a strong combination
index of below 0.3 (Fig. 3d), suggesting that TAK-165 has
a very strong synergistic effect with AC220 in promoting
the cytotoxicity.
Since AC220 is an FLT3 inhibitor, while TAK-165 is a
HER2 inhibitor, and both of these kinases mediated cel-
lular pathways are involved in mediating cell proliferation
signals6,22,23, we next tested whether the TAK-165/AC220
combination treatment could affect cell proliferation. We
found that TAK-165/AC220 combination was able to
reduce colony formation in ES-2 cells, but not in MDCK
and MRC-5 SV2 cells (Fig. 4a). Since both FLT3 and HER2
are involved in regulating the activation of the Akt/mTOR
complex I (mTORC1) signaling pathway, we next com-
pared the effect of single and combination treatment of
TAK-165 and AC220 in ES-2, Sum159 and Sum149 cells
on the activation of this pathway. We found that TAK-
165/AC220 combination was much more effective than
treatment with either compound alone in reducing the
phosphorylation of Akt Ser473 site and mTOR
Ser2448 site, the biomarkers of their activation, as well as
that of S6, which is downstream of mTORC1 signaling, in
ES-2 (ovarian cancer), Sum159 (breast cancer) and
Sum149 (triple negative breast cancer) cell lines (Fig. 4b).
On the other hand, the activation of p38 MAPK, which is
important for mediating cellular stress24, was unaltered
after combination treatment in all cell lines (Fig. 4b). These
data suggest that both FLT3 and HER2 may be involved in
mediating the activation of Akt and mTORC1 in these
cells and inhibition of either pathway alone is not sufﬁcient
to block their growth signaling; while combined TAK-165/
AC220 treatment led to inactivation of Akt/mTORC1
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pathway, but not to alternative pathways such as p38
MAPK.
Next, we evaluated whether the effect of TAK-165/
AC220 combination was dependent upon cell prolifera-
tion by treating conﬂuent and therefore non-proliferative
cells, since the cell death induction in this type of con-
dition is considered to be one of the challenges for che-
motherapies25. We plated ES-2 cells and Sum159 cells in
conﬂuent condition and after TAK-165/AC220 combi-
nation treatment for 24 h, we analyzed cell morphology
using phase-contrast microscopy. We found that both cell
lines showed rounded up and necrosis-like morphology
after combined treatment, suggesting that they were dying
(Fig. 4c). This observation was conﬁrmed by a cell death
assay, which showed a signiﬁcant loss of cell viability in
both ES-2 and Sum159 cells in a dose-dependent manner
after TAK-165/AC220 combination treatment (Supple-
mentary Figure 2A).
TAK-165 inhibits autophagy in a HER2-independent
manner
We have previously shown that the combination of
AC220 with Spautin-1, an autophagy inhibitor, is able to
induce cell death in cancer cells16. Thus, to investigate the
mechanism of cell death caused by the TAK-165/AC220
combination, we next evaluated whether TAK-165 has
any effect on autophagy. Interestingly, we found that
TAK-165 was able to reduce LC3 lipidation in a dose-
dependent manner when stimulated by Rapamycin, an
mTORC1 inhibitor, in ES-2 cells (Fig. 5a, left) or by
AC220, which mimics glucose-free conditions, in HEL
cells (Fig. 5a, right). Moreover, TAK-165 reduced LC3
puncta formation upon autophagy induction by Rapa-
mycin treatment in ES-2 cells (Fig. 5b). These experi-
ments suggest that TAK-165 can potently inhibit LC3
lipidation, a critical step in autophagy. We also assessed
whether treatment with TAK-165 would be reducing
Fig. 1 Identiﬁcation of TAK-165 as a compound that increases the cytotoxicity of AC220 in ES-2 cells. a Outline of high-throughput screen of
cytotoxicity of 12,640 compounds with or without AC220 in ES-2 cells. b Left panel: Fold cell survival data for the screened compounds with (y-axis)
or without (x-axis) AC220, with respect to untreated control. Right panel: Student’s t test with respect to untreated control showing the most
statistically signiﬁcant hits. TAK-165 was discovered among the top 45 hits that did not induce cell death alone, but induced cell death in
combination with AC220. c TAK-165 (Mubritinib) chemical structure. d Dose-response curve of TAK-165 alone and in combination with AC220 in ES-2
cells. ES-2 cells were treated with TAK-165 at indicated concentrations and AC220 at 2 μM for 24 h. Viability was determined using CellTiter-Glo®
Luminescent assay (n = 3). Bars: Mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001
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autophagic ﬂux. As shown in Fig. 5c, after treatment with
the lysosomal inhibitor Chloroquine, TAK-165 (at two
different concentrations), and upon autophagy stimula-
tion by glucose-free conditions, we observed a reduction
of LC3 lipidation, demonstrating that TAK-165 inhibits
autophagic ﬂux under both basal level and glucose-free
conditions.
Since TAK-165 is a HER2 inhibitor17, we next evaluated
whether the autophagy inhibition induced by TAK-165 is
due to HER2 inhibition. We performed HER2 knockdown
Fig. 2 TAK-165 in combination with AC220 induces cell death in breast, AML, and breast triple negative cancer cell lines. a Cell viability (%)
of breast cancer (Bcap-37, MCF-7 and Sum159), b AML (HEL, MOLM-14 and OCI-AML3), c triple negative breast cancer (Sum149 and HCC1937), and d
non-cancer cell lines (MDCK and MRC-5 SV2) treated with TAK-165 (125 nM) and AC220 at 2 different concentrations (1 and 2 μM) for 24 h. Viability
was determined using Sulforhodamine B assay (Breast cancer cells) and CellTiter-Glo® Luminescent assay (AML, breast triple negative and non-cancer
cell lines). In all the experiments, treatment groups were compared with control group, unless otherwise indicated (n = 3). Bars: Mean ± SD. *p < 0.05;
**p < 0.01; ***p < 0.001
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in ES-2 cells using two different shRNAs (Fig. 5d).
However, HER2 knockdown (shHER2) was not able to
inhibit autophagy in ES-2 cells under glucose-free con-
dition (Fig. 5e). Similar to the scramble clone, both
shHer2 clones were sensitive to TAK-165/AC220 com-
bination while the loss of viability was not observed when
exposed to AC220 alone (Fig. 5f). In addition, we also
evaluated whether the use of Lapatinib, another known
HER2 inhibitor, would be able to inhibit autophagy. As
shown in Fig. 5g, no effect on LC3 lipidation was observed
following Lapatinib treatment in glucose-free condition.
Furthermore, Lapatinib and AC220 combination was not
able to induce cell death in ES-2 cells (Supplementary
Fig. 3A). Overall, these data suggest that TAK-165 can
inhibit autophagy in a HER2-independent manner.
Activation of chaperone-mediated autophagy by TAK-165/
AC220 combination induces cell death
To investigate the mechanism of cell death induced by
TAK-165/AC220 combination, we employed zVAD.fmk, a
pan-caspase inhibitor that strongly blocks apoptotic cell
death; as well as three necroptosis inhibitors: Nec-1s
(RIPK1 inhibitor), necrosulfonamide (NSA, MLKL inhi-
bitor) and GSK’872 (RIPK3 inhibitor). As shown in Fig. 6a,
none of these inhibitors prevented the loss of viability
induced by TAK-165/AC220 combination and no caspase-
3 or PARP cleavage was detected after 8 or 16 h of treat-
ment (Fig. 6b). These data indicate that TAK-165/AC220
combination induces neither apoptosis nor necroptosis.
Since we have shown that autophagy inhibition by Spautin-
1 in combination with AC220 lead to chaperone-mediated
Fig. 3 TAK-165 synergizes with AC220 to kill cancer cells. Combination between TAK-165 and AC220 showed a synergistic effects in cancer cell
lines. a ES-2 (b) HEL and (c) OCI-AML-3 were exposed to TAK-165, AC220 or a combination of TAK-165 plus AC220 at three or four different
concentrations (0.01, 0.1, 1 and 10 μM) for 24 h and analyzed by MTT. d The combination index was determined by CompuSyn software using the
results of MTT
Ouchida et al. Cell Death and Disease  (2018) 9:138 Page 5 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
Fig. 4 (See legend on next page.)
Ouchida et al. Cell Death and Disease  (2018) 9:138 Page 6 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
autophagy (CMA) activation and consequent cell death of
cancer cells16, we next explored whether the combination
TAK-165/AC220 also induces CMA. As observed in Fig. 6c,
the combinatorial treatment between TAK-165 and AC220
induced the degradation of different CMA substrates,
including mutant p53, IκB-α, GAPDH and HK2 in a time-
dependent manner in ES-2 cells. CMA activation was also
observed in other cell lines such as breast cancer cells (MDA-
MB-231, Sum159 and MDA-MB-435), and an AML line
(HEL, Supplementary Fig. 4A). To determine whether the
degradation of these proteins is mediated through lysosomal
or proteasomal pathways, we used the protease inhibitor
MG132 or the lysosomal inhibitor chloroquine (CQ) con-
comitantly with TAK-165/AC220 combination and exam-
ined the levels of mutant p53 as a biomarker for CMA
activation. As shown in Fig. 6d, while the treatment of
MG132 further reduced the levels of mutant p53, CQ
treatment recovered mutant p53 levels when used con-
comitantly with TAK-165/AC220 combination. These
results suggest that TAK-165/AC220 combination induces
the degradation of mutant p53 through lysosomal pathway.
Hsc70 and Lamp2A are two key mediators of CMA26–28.
To test the involvement of CMA, we used siRNAs to
knockdown Hsc70 (siHsc70) and Lamp2A (siLamp2A).
We observed a blockage in reduction of mutant p53, HK2,
and GAPDH levels after TAK-165 and AC220 combina-
torial treatment (Fig. 6e), as well as a partial recovery of
cell viability of ES-2 cells upon combined treatment of
TAK-165 and AC220 (Fig. 6f). These results suggest that
the cytotoxicity of combined TAK-165 and AC220
treatment is at least in part mediated through CMA. To
investigate whether CMA activation would be connected
to HER2 inhibition, we used Lapatinib along with AC220
and evaluated mutant p53 levels. We did not observe
mutant p53 degradation upon Lapatinib and AC220
combined treatment (Supplementary Fig. 4B), which
suggests that the CMA induction is also HER2 indepen-
dent. Thus, these data suggest that the TAK-165/AC220
combinatorial treatment induces cell death in different
types of cancer through CMA activation independent of
HER2.
Discussion
Resistance of cancers to chemotherapeutics is a key
reason that leads to the failure of cancer treatment29,30.
One important strategy to overcome cancer resistance to
chemotherapy is through the use of combinatorial treat-
ments, since it is possible to use two different drugs that
inhibit the key signaling pathway in different ways,
thereby blocking the activation of potential resistance
mechanisms; or by the use of two or more drugs that
target different signaling pathways, leading to impairment
of cancer cell survival31–33. AC220 is a second-generation
class III FLT3 inhibitor that has been tested in phase II
human clinical trials, however, it has been shown that
AC220 may be not sufﬁciently efﬁcacious as a mono-
therapy6,7. In this study, we performed a small-molecule
compound screening to identify potential drugs that
increase the chemotherapeutic efﬁcacy of AC220. Inter-
estingly, we identiﬁed TAK-165 as a new autophagy
inhibitor that can induce cell death in different types of
cancer, but not in non-cancer cells, when combined with
AC220.
TAK-165 (Mubritinib) is a potent, selective and irre-
versible HER2 receptor tyrosine kinase inhibitor that was
tested in phase I human clinical trials17,23. HER2 is a
transmembrane receptor tyrosine kinase that is com-
monly overexpressed in breast cancer cells and promotes
cell proliferation and survival22. Thereby, HER2 inhibition
blocks these signaling pathways to promote cytotoxicity in
cancer cells22,34,35. Our results demonstrate that TAK-165
treatment at nanomolar concentrations concomitantly
with AC220 reduces the viability of ovarian cancer (ES-2),
breast cancer (Sum159, Bcap-37 and MCF-7), AML (HEL,
OCI-AML3 and MOLM-14), as well as triple negative
breast cancer cell lines (Sum149 and HCC1937), sug-
gesting that an off-target effect of TAK-16536 mediates its
synergistic action with AC220, since triple negative breast
cancer cells do not express HER237(Fig. 2 and Supple-
mentary Figure 1). These data suggest that TAK-165 can
work to synergistically improve AC220 efﬁcacy in several
types of cancer cell lines independent of HER2.
The comparison between normal tissues and solid
tumors shows that tumors tend to exhibit high cell density
due to rapid growth and high proliferative activity of
cancer cells, which might in part contribute to the resis-
tance to chemotherapeutic treatment38–40. Our results
demonstrate that the TAK-165/AC220 combination is
able to induce cell death in both ES-2 and Sum159 cells,
in a conﬂuent and non-proliferative state (Fig. 4c). In
(see ﬁgure on previous page)
Fig. 4 TAK-165/AC220 combination affects cellular proliferation of cancer cells. a TAK-165 in combination with AC220 suppressed the growth
of ovarian cancer cells but not of non-cancer cells. Colony formation assay for ES-2, MDCK and MRC-5 SV2 cells treated with TAK-165 (125 nM) and
AC220 (2 μM) for 24 h. Right panel shows the quantitative analysis of the colony forming assay. The colony number was determined by ImageJ. b
Immunoblotting of phospho- and total Akt, p38, mTOR and pS6 levels of ES-2, Sum159 and Sum149 treated with TAK-165 (125 nM) and AC220 (2 μM)
for 2 h. Anti-β-actin was used as a loading control. c TAK-165/AC220 combination treatments reduces viability of ES-2 and Sum159 cells in a non-
proliferative state (at 100% conﬂuence). ES-2 and Sum159 cells were treated with TAK-165 (125 nM) and AC220 (2 μM) for 24 h and visualized under a
phase-contrast microscope (magniﬁcation: 200×)
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addition, we have found that TAK-165/AC220 combina-
tion affects cell proliferation of cancer cells, but not that
of non-cancer cells, such as MDCK and MRC-5 SV2
(Fig. 4a). Moreover, the TAK-165/AC220 combination
also potently inhibits the activation of key intracellular
signaling pathways (Fig. 4b), including Akt and
mTORC141–44. In summary, our data suggest the use of
TAK-165 and AC220 is able to induce cell death in both
proliferative and non-proliferative conditions.
Classic autophagy inhibitors may show characteristic
reduction of LC3-II, indicating a blockage in the lipidation
of LC3-I45–47. Such examples include class III PI3K inhi-
bitors, such as 3-methyladenine, Wortmannin and
LY29400245,48, which can inhibit autophagy in early
stages. On other hand, CQ, Hydroxychloroquine, and
Baﬁlomycin A inhibit autophagy at late stages by sup-
pressing the lysosomal function49–51. Our results
demonstrate that TAK-165 is able to reduce LC3-I lipi-
dation upon autophagy activation by combined treatment
with Rapamycin or in glucose-free conditions, which
inhibit mTOR and mimic nutrient deprivation, respec-
tively52,53. In addition, treatment with CQ and glucose-
free conditions shows that TAK-165 reduces the autop-
hagic ﬂux (Fig. 5c). Furthermore, autophagy inhibition
induced by TAK-165 is triggered independently of HER2
(Fig. 5d, e), reinforcing that TAK-165 has an off-target
effect that can inhibit autophagy.
Our data also demonstrate that TAK-165 and AC220
act synergistically in the induction of cell death in dif-
ferent cell lines (Fig. 3). Although all cancer cells tested
have shown a strong combination index (CI), HEL and
OCI-AML3 cells, both AML cells, presented distinct CI
values. This fact might be due to the differential sensitivity
of these cells to TAK-165 and/or AC220 alone treatment.
Other previous studies have demonstrated that AC220
acts synergistically with other compounds inducing cell
death, as follows: (i) the histone deacetylase inhibitor
Panabinostat;54 (ii) the DNA methyltransferase inhibitor
5-azacitidine;9 (iii) receptor tyrosine kinase inhibitors,
such as Dasatinib55 and Sorafenib56, and (iv) JQ1, a BET
protein antagonist, a transcriptional regulatory protein57.
However, this is the ﬁrst report of AC220 acting syner-
gistically with an autophagy inhibitor, suggesting the
possibility of using other autophagy inhibitors in combi-
nation with AC220 to enhance its efﬁcacy in
chemotherapy.
The TAK-165/AC220 combination potently activates
CMA, as evidenced by the degradation of known CMA
substrates, including mutant p53, GAPDH, IκB-α and
Hexokinase-II (Fig. 6c and Supplementary Fig. 4)16,28,58,59.
In addition, both cell viability and degradation of these
substrates are recovered upon Hsc70 and Lamp2A
knockdown, as well as by CQ lysosomal inhibition
(Figs. 6d, e, f), suggesting that the activation of CMA is at
least in part responsible for the cytotoxicity of combina-
tion treatment. CMA promotes the degradation of pro-
teins individually selected by the chaperone-recognition
motif in their amino acid sequence and delivered directly
to the lysosome for degradation. Thus, CMA allows the
removal of speciﬁc proteins and makes it an efﬁcient
system for degradation of damaged or abnormal pro-
teins26,60,61. In addition, the malfunction of CMA may
contribute to cancers;62 however, the activation of this
pathway may induce an increase in proliferation63, or even
cell death16,59,64,65, demonstrating that CMA may play a
double role in cancer. Previously, our group have shown
that Spautin-1/AC220 combination also induces CMA in
cancer cells16. However, Spautin-1 may have cardiotoxi-
city in mice59. Thus, the use of TAK-165 in a combina-
torial treatment may have potential value, since TAK-165
had been tested in a phase I human clinical trials and is
able to inhibit autophagy at nanomolar concentrations.
Therefore, in this study, we identiﬁed for the ﬁrst time the
compound TAK-165 as an autophagy inhibitor, which
promotes cell death in different cancer cells through
CMA activation when treated in combination with
AC220, that promotes metabolic stress and a strong
dependence of autophagy for cell survival16. Further
(see ﬁgure on previous page)
Fig. 5 TAK-165 inhibits autophagy in a HER2-independent manner. a Immunoblotting of LC3 protein levels in ES-2 and OCI-AML3 cells treated
with decreasing concentrations of TAK-165 and/or 200 nM Rapamycin (Rap) for 16 h (right), or treated in combination with 1 μM AC220 for 16 h (left).
b Immunoﬂuorescence staining of LC3. ES-2 cells treated with TAK-165 (1 μM) and/or Rapamycin (200 nM) for 16 h were immunostained for LC3
(green) and counterstained with DAPI (blue) to localize the nucleus (right). Images were captured using a 63x objective of a laser scanning confocal
microscope. Scale bar: 5 μm. LC3 puncta were quantiﬁed by ImageJ software, using at least ﬁve different images from two separate experiments (left).
c Analysis of autophagic ﬂux of ES-2 cells. Immunoblotting of LC3 protein levels in ES-2 cells, treated with 2 different concentrations of TAK-165 (1000
and 125 nM) and/or 50 μM Chloroquine (CQ - lysosomal inhibitor) for 16 h, in presence or absence of glucose-free (GF) conditions. d HER2 does not
inhibit autophagy. Immunoblotting of HER2 and (e) LC3 protein levels in ES-2 stables cell lines for HER2 knockdown, in presence or absence of
glucose-free conditions for 16 h. f Cell viability (%) of ES-2 stable cell lines for HER2 knockdown treated with AC220 (2 μM) or a combination of TAK-
165 (125 nM) plus AC220 for 24 h. Viability was determined using CellTiter-Glo® Luminescent assay (n = 3). g Immunoblotting of LC3 protein levels in
ES-2 treated with decreasing concentrations of Lapatinib and/or glucose-free (GF) conditions for 16 h. Anti-β-tubulin and anti-β-actin were used as a
loading control. In all the experiments, treatment groups were compared with control group, unless otherwise indicated. Bars: Mean ± SD. ***: p <
0.001
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studies should be performed in order to clarify about the
mechanism of action as well as off-target effects of TAK-
165, since our treatment strategy demonstrates its
potential in combinatorial treatment.
Material and methods
Cell culture and treatment conditions
Cells lines were cultured as described previously16. The
triple negative cell lines, Sum149 and HCC1937, were
maintained in RPMI-1640 supplemented with 10% fetal
bovine serum (FBS), penicillin (100 U/ml), and strepto-
mycin (100mg/ml) at 37 °C in a humidiﬁed atmosphere
containing 5% CO2. The non-cancer cell line MRC-5 SV2
was maintained in DMEM supplemented with 10% FBS,
penicillin (100 U/ml), streptomycin (100mg/ml), 2 mM
Glutamine and 1% MEM Non-essential Amino Acid
Solution at same conditions described above. Treatments
were performed either at non-conﬂuent conditions (~60%
conﬂuence) or 100% conﬂuent conditions. For glucose-free
conditions, cell culture media with no glucose was sup-
plemented with dialyzed FBS. TAK-165 (125 nM; Selleck
Chemicals, Texas, USA) and AC220 (2 μM; Selleck Che-
micals) were used unless otherwise stated. Lapatinib (125
nM; Sigma-Aldrich, Missouri, USA), zVAD.fmk (20 μM,
Sigma-Aldrich), Nec-1s (R-7-Cl-O-Nec-1–10 μM), NSA
(Necrosulfonamide, 1 μM, Sigma-Aldrich) or GSK’872 (10
μM, Millipore, Massachusetts, USA) co-treatment was
used to inhibit apoptosis or necroptosis. DMSO (0.1%) was
used as a control. For autophagy induction, Rapamycin
(200 nM; Sigma-Aldrich) was used. Chloroquine (50 μM;
Sigma-Aldrich) and MG132 (10 μM; Sigma-Aldrich) were
added in the last 4 h of the treatment. For cells in non-
proliferative state, phase-contrast imaging was performed
for each cell line after combination treatment for 24 h. A
series of digital images were acquired to cover the entire
well plate using a Nikon Eclipse Ti-E microscope (Japan).
Generation of ES-2 shHER2 cells and Hsc70 and Lamp2A
knockdown
pLKO.1puro lentiviral plasmid (Sigma-Aldrich) was used
to generate ES-2 cells that stably express the short-hairpin
RNA against human HER2 (NC_000017) or non-targeting
shRNA. The two target sequences for shRNA against
human HER2 were: clone 1 (TRCN0000039878) 5′-
GTGTCAGTATCCAGGCTTTGTA-3′, and clone 2
(TRCN0000039882) 5′-GGAATATGTGAACCAGCCA-
GAT-3′. The non-targeting sequence of shRNA (SHC002),
which targets no known mammalian genes, is 5′-CAA-
CAAGATGAAGAGCACCAA-3′. shRNA lentivirus and
cell generation were prepared as previously described66. For
Hsc70 and Lamp2A knockdown, ES-2 cells were trans-
fected with siRNA against Hsc70 and Lamp2A (Gen-
Pharma, China), as well as scrambled siRNA (GenPharma,
China), as negative control, using LipoFectamine RNAi-
MAX reagent (Thermo Fisher Scientiﬁc, Massachusetts,
USA) according to the manufacturer’s instructions. After
48–72 h, knockdown efﬁciency was monitored by immu-
noblotting analysis.
Chemical library screening
The screening for compounds that enhance AC220
efﬁciency as chemotherapeutic agent was performed in
ES-2 cells seeded in 384-well plates under non-conﬂuent
condition 24 h prior to the compound transfer. A total of
12,640 compounds from the ICCB Known Bioactive
Libraries were individually transferred to the wells, and
AC220 (2 μM) was added next to all the wells. After
incubating for 24 h, CellTiter-Glo® Luminescent Cell
Viability assay (Promega, Wincosin, USA) was performed.
Primary hits were based on Z scores calculated using the
formula Z= (X − Ave_Neg)/ SD_Neg or more than 70%
of difference in cell death between library alone and in
combination with AC220. In all, 45 compounds were
identiﬁed from the primary screening and cherry-picked
for a secondary screen. The plates were screened in
duplicates. Spautin-1 (C43) (10 μM) and AC220 (2 μM) in
combination were used as a positive control for cell death.
Sulforhodamin B assay and CellTiter-Glo® Luminescent
viability assay
Sulforhodamine B (SRB) viability assay was performed
as described previously67. Brieﬂy, cells were seeded in 96-
well plates 24 h prior to treatment. The cells were treated
with different concentrations of TAK-165 and AC220, as
(see ﬁgure on previous page)
Fig. 6 TAK-165/AC220 induces cell death through Chaperone-mediated autophagy activation. a Cell viability (%) of ES-2 cells treated with
treated with TAK-165, AC220 or a combination of TAK-165 plus AC220 in the presence or absence of zVAD.fmk, Nec-1s, NSA and GSK832 for 24 h (n =
3). Viability was determined using CellTiter-Glo® Luminescent assay. b Immunoblotting of caspase-3 and PARP-1 in ES-2 cells treated with TAK-165
(125 nM) and/or AC220 (2 μM) for 8 and 16 h. c TAK-165/AC220 combination activates chaperone-mediated autophagy. Immunoblotting of p53, IκB-
α, GAPDH and HK2 levels in ES-2 cells treated with TAK-165 and/or AC220 up to 16 h. d Immunoblotting of p53 levels in ES-2 cells treated with TAK-
165 and AC220 for 6 h in the absence or presence of MG132 (10 μM, proteasome inhibitor) and Chloroquine (CQ, 50 μM). e Immunoblotting of
Lamp2A, Hsc70, p53, HK2 and GAPDH levels in Scramble, Hsc70, or Lamp2A siRNA-transfected ES-2 cells treated with TAK-165 (125 nM) and AC220 (2
μM) for 8 h. f Cell viability (%) of scramble, Lamp2A, or Hsc70 siRNA-transfected ES-2 cells treated with TAK-165 and/or AC220 for 8 h. Viability was
determined using CellTiter-Glo® Luminescent assay (n = 3). Anti–β-tubulin and anti-β-actin were used as a loading control. In all the experiments,
treatment groups were compared with control group, unless otherwise indicated. Bars: Mean ± SD. ***p < 0.001
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described above. After 24 h of incubation, the plates were
washed with 1x PBS twice. Then the cells were ﬁxed with
ice-cold 3.3% TCA at 4 °C for 1 h. After incubation, the
plates were washed thoroughly with water and dried at
room temperature. SRB solution (0.057%) was added to
the plates and incubated at room temperature for 30 min.
The plates were then washed with 0.01% acetic acid
solution and dried at room temperature. Tris solution
(10 mM pH 10.5) was added in each well and the plates
were shaken on an orbital shaker for 5 min at room
temperature. Absorbance was determined at 510 nm
using a Biotek (Vermont, USA) microplate reader. Cell-
Titer-Glo® Luminescent viability assay was also used to
determine cell viability according to the manufacturer’s
instructions.
Immunoblotting and antibodies used
Cells were collected and lysed using RIPA buffer (150mM
NaCl, 1% IGEPAL® CA-630, 0.5% sodium deoxycholate,
0.1% SDS and 50mM Tris-HCl pH 8) supplemented with
protease and phosphatase inhibitors (Roche, Switzerland)
and total protein concentration were measured by BCA
assay. Whole-cell lysates (~20–30 μg of proteins) were
separated by SDS-PAGE and transferred to a nitrocellulose
membrane. Immunoblotting was performed using the fol-
lowing primary antibodies: anti-p38 (#8690), anti-phospho
p38 (T180/Y182 - #4511), anti-p53 (#2524), anti-phospho
pS6 (S235/236 - #4058), anti-Akt (#9272), anti-phospho-
Akt (S473, #4060), anti-caspase-3 (clone 8G10; #9665), anti-
HK2 (#2867), anti-HER2 (#2165), anti-mTOR (#2983), anti-
phospho-mTOR (S2448—#5536), anti-PARP (#9542) from
Cell Signaling Technology (Massachusetts, USA); anti-LC3
(L7543) from Sigma-Aldrich; anti-Actin (sc-8432), anti-
GAPDH (sc-166545), anti-IκB-α (sc-371), anti-Lamp2 (sc-
18822) and anti-tubulin (sc-73242) from Santa Cruz Bio-
technology (Texas, USA); and anti-Hsc70 (10654–1-AP)
from Proteintech (Illinois, USA).
Immunoﬂuorescence for LC3 puncta formation assay
Cells were seeded in glass coverslips in 24-well plate and
treated as described above for 16 h. Samples were ﬁxed with
4% paraformaldehyde (Sigma-Aldrich) for 30min at room
temperature. LC3 primary antibody (L7543, Sigma-Aldrich)
was incubated overnight. Cells were washed 3 times with
PBS-T, incubated with an Alexa Fluor 488-conjugated
secondary antibody for 1 h, counterstained with DAPI
(Thermo Fisher Scientiﬁc). Cells were visualized in a Con-
focal LSM 710 microscope Zeiss (Germany), and analyzed
by Zen Lite software (Zeiss). The number of LC3 puncta/
ﬁeld was determined by an ImageJ software version 1.47t.
Colony formation assay
Cells were seeded in 6-well plates and treated as
described above for 24 h. These cells were counted, and
reseeded in 100mm plates (1000 cells per plate) and
maintained in incubator at 37 °C in a humidiﬁed
atmosphere containing 5% CO2 for 14 days. Culture
media were changed each 4 days. The cells were then ﬁxed
with 4% paraformaldehyde for 15min at room tempera-
ture. The ﬁxed cellular monolayer was washed with 1×
PBS, and 0.1% crystal violet was added and incubated for
20min at room temperature. After incubation time, the
plates were washed with 1× PBS and dried at room tem-
perature. The plates were scanned in HP scanjet
G2710 scanner and analyzed using ImageJ software version
1.47t.
Combination index determination
Cells were seeded in a 96-well plate 24 h prior to
treatment. In the following day, cells were treated with
TAK-165 at concentrations from 10 to 0.05 μM in com-
bination with AC220 at concentrations from 10 to 0.05
μM. After 24 h of incubation, MTT assay was performed
as described previously68 to measure cell viability. The
method described by Chou-Talalay69 was used to deter-
mine the combination index (CI) by using CompuSyn
software. CI< 1,= 1, and >1 indicate synergism, additive
effect, and antagonism, respectively.
Statistical analysis
GraphPad Prism version 5.01 software was used for
statistical analysis. The data were represented as mean±
SD. P values less than 0.05 were considered statistically
signiﬁcant (*p< 0.05; **p< 0.01; ***p< 0.001) and one-
way ANOVA (Tukey’s Multiple Comparison Test) was
used for all analysis.
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